Print version of this report
TGA Action ID RC-2026-RN-00332-1
Type of Product Medical Device
Product Name/Description EasyScreen Enteric Protozoan Detection Kit (EP001) and and EasyScreen SARS-CoV-2 Detection Kit (RP012). An in vitro diagnostic medical device (IVD)

Affected GS-Call v2.23.28 RoW TDF configurations: Master_TDF_v23 and v26
Problem is limited to Giardia intestinalis target thresholds only.
ARTG Number 224567, 334502
Action Type Product Correction
Action Level Hospital
Hazard Classification Class II
Reason for the Action An updated Target Definition File (TDF v25), deployed 20 April 2026, included changes to the EP001 Giardia result interpretation logic that has not undergone full validation prior to release. Changes to EP001 Giardia interpretation cut-off criteria may have resulted in under-detection of positive results (i.e. false negatives).

To date, no adverse events, confirmed patient harm, or confirmed clinical misdiagnosis have been reported in Australia.

This action was initially undertaken prior to notification to the TGA.

UPDATE 11/09/2026:
Further investigation of discrepancies between PCR and microscopy results for Giardia intestinalis has confirmed that the Giardia-specific calling parameters contained in Master_TDF_v23 and Master_TDF_v26 are insufficiently stringent. Under certain conditions, low-level background fluorescence generated by the EP001 Giardia assay can therefore be interpreted as a positive result (i.e. false positives).
Instructions for Customers/Users Genetic Signatures has contacted impacted facilities to arrange for an update to GS-Call TDF. This TDF also includes the ungrouping of the M and N genes within the EasyScreen SARS-Cov-2 Detection Kit (RP012) to align with how result details are read by the affected customer's Laboratory Information Management System.

A retrospective review and reprocessing of affected results is being performed by Genetic Signatures.

UPDATE 11/09/2026:
Higher-stringency Giardia-specific calling parameters have now been evaluated and validated. Master_TDF_v23 and Master_TDF_v26 will be updated to Master_TDF_v28, which incorporates the validated parameters.

Continue testing in accordance with current laboratory procedures pending implementation of Master_TDF_v28. A Genetic Signatures representative will arrange the TDF update which is planned for internal release on 30 September 2026 and deployment during the week commencing 12 October 2026.
Action Commencement Date 8/05/2026
Responsible Entity Genetic Signatures Ltd
Contact Information (02) 9870 7580 - Genetic Signatures